Central and peripheral administration of atriopeptin is anxiolytic in rats.
Standard
Central and peripheral administration of atriopeptin is anxiolytic in rats. / Ströhle, A; Jahn, Holger; Montkowski, A; Liebsch, G; Boll, E; Landgraf, R; Holsboer, F; Wiedemann, Klaus.
in: NEUROENDOCRINOLOGY, Jahrgang 65, Nr. 3, 3, 1997, S. 210-215.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Central and peripheral administration of atriopeptin is anxiolytic in rats.
AU - Ströhle, A
AU - Jahn, Holger
AU - Montkowski, A
AU - Liebsch, G
AU - Boll, E
AU - Landgraf, R
AU - Holsboer, F
AU - Wiedemann, Klaus
PY - 1997
Y1 - 1997
N2 - The effects of the central and peripheral administration of atriopeptin II, a 23-amino acid residue peptide of atrial natriuretic peptide (Ser103-Arg125) on anxiety-related behavior and on locomotor activity, was studied in male Wistar rats. Their behavior on the elevated plus-maze after social defeat stress indicated that intracerebroventricular (2.5 and 5 micrograms) and intraperitoneal (50 micrograms) administration of atriopeptin II produced anxiolysis. A low dose of 0.25 micrograms atriopeptin II administered bilaterally into the central nucleus of the amygdala was also found to be anxiolytic. Because intracerebroventricular administration of 5 micrograms atriopeptin II did not affect locomotor activity in the open-field test, the possibility that the anxiolytic effect was secondary to sedation could be ruled out. The anxiolytic effects observed after central and peripheral administration support the idea that atrial natriuretic peptide, which is increased in panic-anxiety, may be involved in the tapering of anxiety-related behavior.
AB - The effects of the central and peripheral administration of atriopeptin II, a 23-amino acid residue peptide of atrial natriuretic peptide (Ser103-Arg125) on anxiety-related behavior and on locomotor activity, was studied in male Wistar rats. Their behavior on the elevated plus-maze after social defeat stress indicated that intracerebroventricular (2.5 and 5 micrograms) and intraperitoneal (50 micrograms) administration of atriopeptin II produced anxiolysis. A low dose of 0.25 micrograms atriopeptin II administered bilaterally into the central nucleus of the amygdala was also found to be anxiolytic. Because intracerebroventricular administration of 5 micrograms atriopeptin II did not affect locomotor activity in the open-field test, the possibility that the anxiolytic effect was secondary to sedation could be ruled out. The anxiolytic effects observed after central and peripheral administration support the idea that atrial natriuretic peptide, which is increased in panic-anxiety, may be involved in the tapering of anxiety-related behavior.
M3 - SCORING: Zeitschriftenaufsatz
VL - 65
SP - 210
EP - 215
JO - NEUROENDOCRINOLOGY
JF - NEUROENDOCRINOLOGY
SN - 0028-3835
IS - 3
M1 - 3
ER -